Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus. (PubMed, J Card Fail) - Jun 26, 2025 - "Letermovir holds promise as an effective and safe alternative to valganciclovir for CMV prophylaxis in HT recipients."
Journal • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Neutropenia • Transplant Rejection • Transplantation
|
|
Adel T Alnatour; Adil A Yunis; Afsana Rahman; Andrea Fernandez Valledor; Brain LaBarre; Cathrine M Moeller; Changhee Lee; Daniel Oren; David Bae; David T Majure; Dor Lotan; Edward Lin; Ersilia M DeFilippis; Farhana Latif; Gabriel Sayer; Gal Rubenstein; Jason Choe; Jayant Raikhelkar; Julia Baranowska; Justin Fried; Kevin J Clerkin; Kyung Taek Oh; Melana Yuzefpolskaya; Nir Uriel; Paolo C Colombo; Salwa Rahman
|